Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

Novartis’ MS therapy Mayzent approved by NICE

Novartis’ MS therapy Mayzent approved by NICE 16 Oct 2020
Mayzent (siponimod), a sphinogosine 1-phosphate receptor modulator, is the first oral disease-modifying treatment recommended by both NICE and the Scottish Medicines Consortium (SMC) for SPMS with active disease. ... According to NICE, around 11, 000

NICE recommends Roche’s Polivy for B-cell lymphoma

NICE recommends Roche’s Polivy for B-cell lymphoma 20 Aug 2020
With the updated information, the treatment is now considered a cost-effective use of NHS resources, said NICE. ... with NICE to reach a deal that not only benefits patients but also has a fair price for taxpayers,” he added.

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer 31 Jul 2020
Picks up approval as a first-line treatment for advanced cancer. The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck KGaA and Pfizer’s immunotherapy Bavencio ... NICE’s positive recommendation also addresses the

NICE recommends Astellas’ Xospata for NHS use

NICE recommends Astellas’ Xospata for NHS use 17 Jul 2020
Cost-effectiveness watchdog backtracks on previous rejection. The UK’s National Institute for Health and Care Excellence (NICE) has recommended Astellas’ Xospata for routine use on the NHS, backtracking on its ... However, following further

Celgene’s Revlimid scores NICE approval in follicular lymphoma

Celgene’s Revlimid scores NICE approval in follicular lymphoma 27 Feb 2020
New ‘chemotherapy-free’ treatment for patients with limited options. Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication ... for Health

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Infographics